Author (year) (reference) | Studied population AS (M/F) | Treatments | Control population (M/F) | MAIT cell identification | Main results | Cytokine profile |
Cho (2014)20 | 21 (19/2) | 0% under biologics or CTC | 54 SLE (3/51) 66 RA (12/54) 9 Behcet (7/2) 136 HC (69/67) | CD3+Vα7.2+CD161high |
| |
Sugimoto (2015)21 | 37 SpA (6/31) (17 AS, 17 uSpA, 1 Psa,1 ReA) | 51% under biologics 48% under CTC | 26 FMS (1/25) 21 RA (2/19) 16 HC (2/14) | CD3+Vα7.2+CD161high |
| |
Hayashi (2016)22 | 30 (28/2) | 50% under biologics 23% under NSAIDs 6% under CTC | 21 HC (20/1) | CD3+Vα7.2+CD161high |
| Higher frequency of IL-17A+ MAIT in the blood of patients with AS compared with HC |
Gracey (2016)23 | 54 (36/18) | 61% under biologics 58% under NSAIDs | 28 HC 16 RA | CD3+Vα7.2+CD161high |
| Higher frequency of IL-17A+ MAIT in the blood of male patients with AS compared with HC Lower frequency of IFNα+ MAIT in the blood of AS compared with HC Priming of MAIT cells by IL-7 |
Toussirot (2018)24 | 36 (27/9) | 100% under NSAIDs 0% under biologics or CTC | 55 (32/23) | CD3+Vα7.2+CD161high |
| Higher number of circulating IL-17A+IFNα+ MAIT and IL-22+ MAIT cells in patients with AS compared with HC |
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; CTC, corticosteroids; FMS, fibromyalgia syndrome; HC, healthy controls; M/F, male/female; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ReA, reactive arthritis; SLE, systemic lupus erythematosus; uSpA, undifferentiated spondyloarthritis.